Search

Displaying results 2731 - 2740 of 10000 in total
  1. Drug

    Iron sucrose

    go.drugbank.com/drugs/DB09146
    ApprovedInvestigational

    Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. … Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis

  2. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    New Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  3. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  4. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

  5. Drug

    Distearyldimonium

    go.drugbank.com/drugs/DB14143
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

  8. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.

  9. Drug

    Dasabuvir

    go.drugbank.com/drugs/DB09183
    Approved

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Dasabuvir as first line therapy … in combination with [DB09296], [DB09297], and [DB00503] for genotype 1b and with [DB00811] for genotype 1a of Hepatitis C [L852].

    Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide
  10. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis. … LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.